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As RNA turnover seems to be impaired in cancer patients, modified nucleosides have
been evaluated as potential tumor markers. Modified nucleosides are mainly formed post-
transcriptionally in tRNA, set free during RNA metabolism, and excreted in urine. Especially
methylated nucleosides play an important role, as their levels are higher in urine from cancer
patients. For structural elucidation of known and unknown nucleosides from urine samples of
cancer patients, MALDI-TOF MS and MALDI-PSD were used for the first time. This technique
generally ensures high sensitivity, mass resolution, and accuracy. In our analytical approach
we prepurified nucleosides from urine by affinity chromatography and subsequently sepa-
rated them by semipreparative high performance liquid chromatography. The different
fractions were collected separately and analyzed by MALDI-TOF MS and PSD-MALDI using
a mixture of six low molecular weight calibrants for internal or external calibration. The
molecular totals formulas based on a mass accuracy of 10 ppm and below were calculated and
a systematic data base search was performed. The inherent problem of the MALDI-technique,
the reduced sensitivity for low molecular weight substances caused by matrix suppression
effects, was reduced by our technique. We identified several nucleosides in urine, which were
previously identified via retention times and UV spectra of standards after HPLC analysis.
Eight further nucleosides were observed. This work demonstrates for the first time the
potential of MALDI-TOF and PSD-MALDI in combination with semipreparative HPLC for
assignment of nucleosides in urine. The particularly high mass accuracy of this mass
spectrometric method provides opportunities for identifying unknown compounds. (J Am
Soc Mass Spectrom 2005, 16, 940–947) © 2005 American Society for Mass SpectrometryMore than 50 different nucleosides have beenidentified in urine from healthy people as wellas from patients suffering from different
kinds of cancer; some have been shown to be elevated
in urine of cancer patients [1, 2]. They are degradation
products of ribonucleic acid (RNA), particularly tRNA
(transfer RNA), and show various modifications [1]. A
number of nucleosides occurring in urine are shown in
Figure 1. Transfer RNA contains a wide variety of
modified nucleosides, which influence the translational
efficiency and precision as well as the sensitivity to the
reading context and the reading frame maintenance.
Nucleosides in precursor tRNA (pre-tRNA) are modi-
fied by enzymes like tRNA-methyltransferases or -syn-
thetases after the transcription. Their function and kind
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doi:10.1016/j.jasms.2005.02.018of modification (methylation, desaminization, conver-
sion of uridine to pseuduridine etc.) depend on their
location in the tRNA chain [1, 3]. After having per-
formed their task, the tRNA molecules are cleaved to
nucleosides. Unmodified nucleosides are recycled for
biosynthesis of new RNA, while modified ones are not
substrates to the salvage enzymes and thus are set free
in the blood circulation and excreted with urine [1, 3]. In
the meantime, 79 different modified nucleosides have
been isolated from tRNA and have been characterized,
all of which are derivatives of the nucleosides adeno-
sine, guanosine, uridine, and cytosine [4]. Dudley et al.
identified a new nucleoside, 5=-deoxycytidine, in the
urine of a patient with terminal head and neck cancer
[5]. In urine of head and neck cancer patients in other
stages of the disease, this nucleoside did not occur.
There may be a relation between cancer stage and the
appearance of 5=-deoxycytidine in urine.
In the case of breast cancer, no reliable tumor mark-
ers for diagnosis in an early stage are available to the
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Union contract a malignant mamma carcinoma during
their life. Only 5 to 10 % are hereditary, while 90 to 95%
occur spontaneously. The stages of mamma carcinoma
are classified by the diameter of the primary tumor
(T-classification), involvement of lymph nodes (N-clas-
sification), and the appearance of distant metastases
(M-classification) [7].
Modified, especially methylated nucleosides have
been shown to be elevated in urine from cancer patients
because of an increased turnover of tRNA in tumor
tissue [8]. Following this, the pattern of modified
nucleosides may be used in tumor diagnosis [9]. It was
shown that the levels of 1-methylinosine and N2,N2-
dimethylguanosine are higher in urine from breast
cancer patients [10]. Increased levels of modified
nucleosides were also observed in urine from patients
suffering from leukemia [11], gastrointestinal cancer
[12], or lung carcinoma [13].
Various methods have been applied for quantifica-
tion of nucleosides in urine. Nucleosides were isolated
from urine by solid phase extraction using phenylbo-
ronic acid gel. Uziel et al. prepared an affinity gel
containing an immobilized phenylboronic acid group,
which specifically binds cis-diols, as in nucleosides [14].
Gehrke and Kuo established an analytical method via
high performance liquid chromatography (HPLC) [15],
which was advanced over the years.
In our approach we used a modified method based
on the work of Liebich et al. [16]. Modifications of the
Figure 1. Structures of selected nucleosides occurring in urine.method were necessary as after the HPLC run, thefractions were examined further by mass spectrome-
try.
In the present work, we developed a method to
examine unidentified nucleosides from urine including
HPLC-separation, matrix-assisted laser desorption/ion-
ization time-of-flight mass spectrometry (MALDI-TOF
MS) and post source decay (PSD). With this method, we
are particularly searching for new nucleoside markers,
which are specifically elevated in urine from mamma
carcinoma patients. Furthermore, the pattern of ele-
vated nucleosides may be characteristic for the type or
cancer stage.
Experimental
Urine Samples
To exemplify our method, the randomly collected urine
of two patients with mamma carcinoma was examined.
The samples were taken preoperatively. One patient
was 80 years old and had an invasive ductal mamma
carcinoma and a low-grade ductal carcinoma in situ
(DCIS). The tumor was smaller than 2 cm and no
involvement of the lymph nodes was diagnosed. The
other patient was 70 years old and had an invasive
lobar mamma carcinoma. The tumor was also smaller
than 2 cm. Metastases were diagnosed in the lymph
nodes. This patient was undergoing chemotherapy
prior to the operation. For comparison, two urine sam-
ples of healthy patients were also examined with HPLC.
Sample Preparation
Before performing the affinity chromatography, the pH
of the urine samples was measured and, if necessary,
alkalized by addition of ammonia to pH 8-9.
The urine was extracted using 500 mg of phenylbo-
ronic acid gel (Affigel 601, Bio-Rad, Munich, Germany).
The gel was activated with 25mL of 0.1M formic acid in
methanol/water (1:1, vol:vol), washed with 25 mL of
methanol/water (1:1) and equilibrated with 35 mL of
0.25 M ammonium acetate, pH 8.5. Then, 10 mL of
centrifuged urine containing 0.5 mL of a 0.25 mM
internal standard solution of isoguanosine was applied
to the column. After washing with 20 mL of 0.25 M
ammonium acetate and twice with 3 mL of methanol/
water (1:1, vol:vol), the nucleosides were eluted with 25
mL of 0.1 M formic acid. The solution was evaporated
and dissolved in 0.5 mL of 25 mM potassium dihydro-
gen phosphate, pH 5.
Reversed-Phase High-Performance
Liquid Chromatography
The liquid chromatography of extracted urine samples
was performed on an Agilent (Waldbronn, Germany)
1100 HPLC at 30 °C with UV detection at 210 and 260
nm. UV spectra (200–600 nm) were recorded over the
whole running time. A 125  2 mm, 4 m LiChroCART
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Germany) was used to separate the nucleosides. The
chromatography was performed using a gradient of 5
mM ammoniumformiate buffer (pH 5.0) (Solvent A)
and methanol/water (3:2, vol:vol) containing 0.1 %
formic acid (Solvent B) over 55 min as shown in Table 1.
Methanol and formic acid were purchased from Merck.
MALDI-TOF Analysis of Nucleosides
The experiments were performed on a time-of-flight
mass spectrometer, model Autoflex (Bruker, Bremen,
Germany) with a 337-nm nitrogen laser. We used an
AnchorChip Target with 0.4 m Anchors (Bruker).
2,5-dihydroxybenzoic acid (DHB) was obtained from
Fluka (Taufkirchen, Germany). -cyano-4-hydroxycin-
namic acid (CHCA) and the nucleosides adenosine (A),
1-methyladenosine (m1A), N6-methyladenosine (m6A),
5=-deoxy-5=-methylthioadenosine (MTA), cytidine (C),
inosine (I), 1-methylinosine (m1I), guanosine (G),
1-methylguanosine (m1G), N2-methylguanosine (m2G),
uridine (U), dihydrouridine (DHU), pseudouridine ()
3-methyluridine (m3U), 5-methyluridine (m5U), and
xanthosine (X) were purchased from Sigma-Aldrich
(Munich, Germany).
Preparation of Matrix
DHB was dissolved in TA solution (0.1% trifluoracetic
acid/acetonitrile, 2:1, vol:vol) to a concentration of 5
mg/mL and sonicated for 5 min. 0.5 L of this freshly
prepared solution was placed upon the MALDI-Target.
For measurements with high mass accuracy, a thin layer
of CHCA (saturated in acetone/ethanol, 1:1, vol:vol)
was used.
Sample Preparation
For the analysis of standard nucleosides, 1 mg/mL
solutions in 0.1% trifluoracetic acid were prepared. 1 L
of these solutions was placed onto 0.5 L of DHB-
solution on target. For determination with high mass
accuracy, a thin layer of CHCA was prepared on the
Anchor Chip target and the analyte solution added
afterwards.
Semipreparative HPLC and MALDI-TOF MS
To analyze the isolated nucleosides in urine samples
from breast cancer patients, different fractions from
semipreparative HPLC separation were collected in 1.5
mL Eppendorf tubes, lyophilized, and solved again in
10 L of 0.1% TFA. The matrix solution for the MALDI-
TOF MS analysis was placed onto the Anchor Chip
target and 1 L of the sample solution was added. After
having recorded the spectra of the different HPLC
fractions, masses between 240 and 450 Da were exam-
ined by Post Source Decay (PSD) to determine the
fragmentation and obtain indications of nucleosides.Calibration
For calibration a standard mixture of caffeine
([C8H11N4O2]
, monoisotopic molecular mass 195.099220),
bamipine ([C19H25N2]
, monoisotopic molecular mass
281.201779), etophylline ([C9H13N4O3]
, monoisotopic mo-
lecular mass 225.098790), phenylbutazone ([C19H21N2O2]
,
monoisotopic molecular mass 309.160320), pyrimethamine
([C12H14ClN4]
, monoisotopic molecular mass 249.090699)
and piritramid ([C27H35N4O]
, monoisotopic molecular
mass 431.281070) was used. An external calibration was
performed before generating overview spectra. To gen-
erate spectra with high mass accuracy, an internal
calibration was performed.
Results and Discussion
Although MALDI-TOF MS is used predominantly for
determination of large molecules like polymers, pro-
teins, and peptides, there have been successful applica-
tions for different classes of small molecules [17].
Lidgard et al. used DHB and CHCA matrix for deter-
mination of nucleosides and other small molecules by
MALDI-TOF MS [18]. In our experiments, DHB was
discovered to be the most suitable matrix for analyzing
nucleosides by MALDI-TOF MS with high sensitivity.
However, we observed reduction of several nucleo-
sides, especially adenosine and its metabolites, as
shown in Figure 2. Similar effects were observed in
previous examinations by Koomen and Russell [19]. To
avoid this, CHCA would be the preferable matrix, but
with less sensitivity.
As DHB is a matrix which usually forms large
crystals, the resulting mass accuracy is not optimal. We
determined a mass accuracy below 100 ppm for exter-
nal and below 40 ppm for internal calibration. With a
thin layer of CHCA matrix, a mass accuracy below 10
ppm was achieved when using internal calibration.
Using DHB matrix, 18 nucleosides were determined
by MALDI-TOF MS. The limits of detection (LOD) vary
from 100 fmol to 10 pmol (S/N 300). The nucleosides of
lower basicity, especially the ones with pyrimidine
base, show a higher LOD than purines, as shown in
Table 2. The resolution usually varies in a range from
5000 to 9000. Dudley et al. determined LOD between 19
and 110 pmol for nucleoside standard solutions mea-
sured by LC-ESI MS [20]. Compared with these results,
Table 1. Solvent gradient of the HPLC separation
Time (min)
Ammoniumformate
buffer 5 mM,
pH 5 [%]
MeOH/H2O bidest
(3/2, vol/vol),
0.1% FA [%]
0 100 0
30 85 15
40 40 60
50 100 0
55 100 0MALDI-TOF MS is the most suitable mass spectromet-
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mass accuracy. Dudley et al. also showed characteristic
fragmentation ions of nucleosides with LC-ESI MS/MS
[20]. ESI MS and MALDI-TOF MS both are soft ioniza-
tion techniques. With MALDI-TOF MS the mass accu-
racy and resolution are usually better, while ESI MS can
be coupled with liquid chromatography. The MS/MS
spectra of MALDI-TOF MS and ESI MS are similar, but
not identical. The major peak in the studies of Dudley et
al. was that of the protonated nucleic base [20]. Analo-
gous fragmentation was seen in our PSD spectra.
The nucleosides decay under loss of 132 Da (ribose),
except pseudouridine, because of the stronger
carbonOcarbon bond between sugar and nucleic base.
Dudley et al. observed the fragments m/z 209, 179, and
155 for pseudouridine [20]. In our PSD-spectrum of
pseudouridine, which is shown in Figure 3, these
masses also occurred. The PSD spectra of the other
standard nucleosides show a characteristic decay be-
tween nucleic base and sugar. The protonated base is
usually the major fragment. Other fragments of differ-
ent intensity also occurred. They could not be assigned
to structural fragments of the corresponding nucleo-
sides yet, but the ones with high intensity still are
characteristic indications for those nucleosides. Iso-
meric nucleosides (like G/isoG, m1G/m2G, m1A/m6A,
and m3U/m5U) show identical characteristic PSD ions.
They need to be identified by comparison with reten-
tion times and UV spectra of the standard substances
after HPLC separation.
Uridine, DHU, 3-methyluridine and 5-methyluridine
produce the same fragment ofm/z 133. DHU produces the
fragments m/z 115, m/z 157 and m/z 181. Uridine shows
corresponding fragments with a difference of 2 Da (m/z
113, m/z 155 and m/z 179). This speaks well for fragments,
which still include the intact pyrimidine base.m/z 155 and
m/z 179 occur in the PSD-spectrum of uridine as well as of
pseudouridine. These fragments can be explained by
Figure 2. MALDI-TOF spectra in reflecting mo
and DHB (b) matrix.fragmentation at S1 and loss of water, as formerly de-scribed by Dudley et al. and shown in Figure 3. The
fragmentation at S1 was first observed by Crow et al. in
examinations of nucleosides by fast atom bombardment
(FAB) [21]. The pyrimidine nucleosides, except cytidine,
show a S1-cleavage such as observed by Crow et al. for
some nucleosides. With chemical ionization mass spec-
trometry, Wilson and McCloskey had also shown that
nucleosides are cleaved in this way [22].
The PSD spectra of adenosine and its metabolites
m1A, m6A, and MTA all contain a fragment of m/z 136.
The nucleic base fragments of the methylated aden-
osines are fragmented further under loss of the methyl
group, generating the adenine base (m/z 136) such as
adenosine and MTA. The methylated adenosines fur-
thermore show a fragment which is caused by an S1
cleavage. The characteristic fragmentation ions of the
analyzed nucleosides and a comparison with fragmen-
tation with FAB and CI are given in Table 3.
Prior to the MALDI-TOF examination, the semi-
preparative HPLC analysis is used to isolate the un-
identified compounds from urine. Ten nucleosides
were identified in the urine samples by retention times
and UV spectra of the individual peaks in the HPLC-
chromatogram (Figure 4). This assignment was con-
firmed by the MALDI and MALDI- PSD results.
Table 2. Limits of detection of standard nucleosides
Nucleoside Limit of detection
Adenosine 100 fmol
1-Methyladenosine 100 fmol
N6-Methyladenosine 100 fmol
MTA 100 fmol
Cytidine  2 pmol
Guanosine  2 pmol
Inosine  10 pmol
Uridine  4 pmol
Pseudouridine  10 pmol
adenosine. Isotope distribution with CHCA (a)de ofXanthosine  2 pmol
m a
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standard solution were not found in our urine
samples. Uridine, 3-methyluridine, 5-methyluridine,
N6-methyladenosine, and guanosine do not seem
to be present in significant amounts, as neither
Figure 3. Post source decay spectru
Table 3. Comparison of fragmentation ions of nucleosides gene
Nucleoside
Characteristic fragmentions
(m/z) in PSD spectra
Adenosine 136, 166, 181 268
1-Methyladenosine 136, 150, 180, 192 n.i.
N6-Methyladenosine 136, 150, 180, 192 n.i.
MTA 136, 163 n.i.
Cytidine 112, 137, 228 244
Inosine 137, 261 n.i.
1-Methylinosine 136, 151, 201, 271 n.i.
Guanosine 136, 152, 271, 194 266
Isoguanosine 136, 152, 271 n.i.
1-Methylguanosine 166, 136, 211 298
2-Methylguanosine 166, 136, 211 298
DHU 115, 133, 157, 181, 229 247
Uridine 113, 133, 155, 179, 231 245
3-Methyluridine 127, 133, 169 259
5-Methyluridine 127, 133, 169 n.i.
Pseudouridine 155, 179, 209, 113 245
Xanthosine 136, 153, 200, 271 n.i.Bold: nucleic base fragment, n.i.: not investigatedthe HPLC-run nor the determination by MALDI-
TOF offer clues to their presence. In the analyti-
cal work of Xu et al., these nucleosides were also
minor components in urine samples of cancer pa-
tients [23].
nd fragmentation of pseudouridine.
by PSD-MALDI, FAB and CI
FAB [18] CI [19]
, 237, 178, 164, 136 268, 136, 164, 178, 135, 150, 176
268, 136, 164, 150, 178, 192
282, 150, 178, 192, 136
n.i.
, 140, 133 244, 112, 140, 154
n.i.
n.i.
, 194, 180, 152 n.i.
n.i.
, 208, 194, 166 n.i.
, 180, 166 n.i.
, 157, 143, 115, 133 n.i.
, 155, 141, 113, 133 245, 113, 141, 155
, 169, 155, 127, 133 n.i.
n.i.
, 214, 155, 137, 133, 209 245, 113, 141, 155, 179, 209
n.i.rated
, 250
, 154
, 253
, 267
, 208
, 229
, 227
, 241
, 227
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by Database Search
A high mass accuracy is necessary for calculation of
totals formulas with given elemental composition. For
this calculation, Molecular Weight Calculator 6.22 (Mat-
thew Monroe, http://www.alchemistmatt.com) was
used. Nucleosides contain a minimum of nine carbon
atoms, three oxygen atoms, and two nitrogen atoms.
With a mass accuracy of 10 ppm and looking for
compounds fulfilling these restrictions, it is possible to
narrow the number of totals formulas down to a few.
The suggested totals formulas are then used to search
for nucleoside structures systematically. For this search,
SciFinder 2003 was used.
As a proof of concept experiment, a xanthosine stan-
dard was measured with the monoisotopic mass
285.0818 (based on a mass accuracy of 10 ppm using
internal calibration). For this mass and mass accuracy,
Molecular Weight Calculator calculated 24 different
totals formulas. Only one of the formulas fulfilled the
conditions for elemental composition of nucleosides as
described above. The search by SciFinder resulted in
132 hits, which were narrowed down to 40 compounds
containing ribose. One of these compounds was xan-
thosine. In connection with the characteristic PSD spec-
trum, xanthosine could be identified. This example
shows that with an accurate mass in connection with
the fragmentation it is possible to obtain hints on the
structure of unknown compounds.
Figure 4. High performance liquid chromatogr
cancer patient.In the HPLC fractions 12 and 16, new compoundswith m/z 271 and the fragment ion m/z 139 occurred.
Both fractions were analyzed with the described
method. In fraction 16, m/z 271.0918 was measured and
16 different totals formulas were proposed. After nar-
rowing the results by the restrictions mentioned above,
two possible formulas remained. One of them led to no
hits when searching by SciFinder. The other one re-
sulted in 323 hits, which were narrowed to 33 com-
pounds containing ribose. Two of these compounds are
1-ribosylpyridin-4-one-3-carboxamide and 1-ribosyl-
pyridin-2-one-5-carboxamide (structures shown in
Figure 5). The other suggested structures were not
naturally occurring compounds. Dutta et al. isolated
1--D-ribofuranosylpyridin-4-one-3-carboxamide from
human urine in 1979 [24]. 1-Ribosylpyridin-4-one-3-
chromatogram of a urine sample from a breast
N
O
OHOH
H H
OH
O O
NH2
NO
O
OHOH
H H
OH
O
NH2
(a) (b)
Figure 5. Structures of 1-ribosylpyridin-4-one-3-carboxamide (a)aphyand 1-ribosylpyridin-2-one-5-carboxamide (b).
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ide were isolated and identified from human urine in
1989 by Mills et al. [25] Both compounds are likely to be
ingredients of the examined urine samples, as two
HPLC fractions contain m/z 271 producing the fragment
139. The likely sources of these nucleosides are NMN or
NAD [26].
Fraction 2 contained an unidentified m/z 255, which
was analyzed with the described method as well, but
only synthetically prepared structures were proposed.
Further investigations for elucidation are in progress.
Other nucleosides were observed. These are a meth-
ylated cytidine (m/z 258), an acetylated cytidine (m/z
286), another methylated guanosine (m/z 298), a double
methylated guanosine (m/z 312), a triple methylated
guanosine (m/z 326), and a nucleoside with m/z of 413.
This nucleoside is likely N6-threonylcarbamoyladen-
osine (t6A).
As the two methylated guanosines, 1-methyl-
guanosine and N2-methylguanosine, already were
identified in urine with this chromatographic system,
the most likely position for another methyl group is N7.
N7-methylguanosine is another methylated nucleoside,
which has been identified earlier in human urine.
N2,N2-dimethylguanosine and N6-carbamoylthreo-
nyladenosine have been evaluated as tumor markers in
breast cancer patients in former studies [27]. As de-
scribed, we could also identify the masses with the
corresponding fragments of these nucleosides in urine
from breast cancer patients. Both nucleosides are major
compounds in the urine samples, which is consistent
with the previous observations.
One peak contained m/z 326, PSD produced a m/z
fragment 194, indicating the presence of a triple meth-
ylated guanosine. We assume that it is N2,N2,7-tri-
methylguanosine, the only known naturally occurring
trimethylguanosine with three methyl groups at the
base moiety. N2,N2,7-trimethylguanosine was de-
scribed to be part of mRNA and snRNA [4, 28]. The
results of the database search for the examined fractions
Table 4. MALDI-TOF MS and PSD MALDI results
HPLC
fraction
RT
[min:sec]
m/z [Da]
(mass accuracy [ppm])
C
2 5:00–6:00 255.09817 114,
8 12:20–15:00 258.10966, (2.6,IC) 126,
12 19:30–21:30 271.09417, (4.3,IC) 139,
14 23:00–24:20 298.11331, (6.2,IC) 166,
16 26:00–27:40 271.09257, (1.6,IC) 139,
24 37:30–38:40 308.08740a, (4.5,IC) 154,
29 42:00–43:40 326.14514, (4.0,IC) 136,
30 43:00–43:50 312.12905, (5.4,IC) 138,
33 46:20–47:00 413.13964, (5.9,IC) 136,
Numbers in bold represent nucleic base fragments
IC: internally calibrated
asodium adductare shown in Table 4.Conclusions
To the authors’ best knowledge this is the first time that
nucleosides from urine were analyzed by MALDI-TOF
and PSD-MALDI. We achieved a very high sensitivity
and mass accuracy for nucleosides measured by mass
spectrometric methods. It could be shown that nucleo-
sides can be analyzed by MALDI-TOF MS using CHCA
matrix with limits of detection between 100 fmol and 10
pmol. The mass accuracy was below 10 ppm when
using internal calibration.
PSD spectra of twelve nucleosides show that purines as
well as pyrimidines decay under neutral loss of the sugar
producing the nucleic base as a fragment. Other fragments
enhance the selectivity, as they are characteristic for the
different nucleosides, except those with isomeric nucleic
bases, which produce similar PSD spectra.
After extraction from urine by affinity chromatography
and separation via reversed-phase HPLC, several small
molecular masses were observed and determined by
PSD-MALDI-TOF. Some compounds could be identified
as nucleosides, while others seem to be nucleosides that
could not yet be identified. A number of masses did not
provide any indication of being nucleosides.
With the described method including affinity chro-
matography, semipreparative liquid chromatography,
and MALDI-TOF MS, it is possible to propose struc-
tures for nucleosides from urine. After having identi-
fied new nucleosides, they should be examined for their
potential as tumor markers by quantifying and compar-
ing both the concentrations and the entire nucleoside
pattern of cancer patients and healthy subjects.
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